MedTrace Logo

Evaluation of Mammographic Breast Density in Participants with Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502

NCT03609021 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2025-01-16

No results posted yet for this study

Summary

This phase III trial evaluates mammographic breast density in participants with hormone receptor-negative breast cancer enrolled on study A011502. High breast density has been shown to be a strong risk factor for developing breast cancer and decreasing breast density may decrease the risk for breast cancer. Participants treated with aspirin may show reduced breast density on a mammogram.

Conditions

  • Breast Carcinoma
  • Estrogen Receptor Negative
  • Progesterone Receptor Negative

Interventions

PROCEDURE

Screening Mammography

Provide bilateral mammogram

PROCEDURE

Biospecimen Collection

Undergo collection of blood sample

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Alliance for Clinical Trials in Oncology

    lead OTHER

Principal Investigators

  • Marie Wood, MD · University of Vermont

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-26
Primary Completion
2022-07-15
Completion
2022-07-18

Countries

  • United States
  • Guam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03609021 on ClinicalTrials.gov